Moreover, molecular docking analysis elucidated 80a could bind to both the entrance and the substrate cavity of MAO-B, indicating that the development of agents with multi-target-directed targets was a useful strategy for treating AD. This evidence concerns the gene MAOB and Alzheimer disease.